close

Fenwick Representation of Cepheid in $4B Acquisition by Danaher Covered Nationally

September 06, 2016

Fenwick’s representation of Cepheid, a leading molecular diagnostics company, in its $4B acquisition by Danaher Corporation was covered by Fortune, Reuters, CNBC, Law360 and The American Lawyer​ (subscriptions may be required).

“We expect Cepheid to be an excellent complement to our existing diagnostics businesses and to expand our runway for growth across the platform,” Thomas P. Joyce Jr., Danaher president and CEO, said in a statement quoted by Law360.

“Cepheid’s extensive installed base, test menu and innovative product offering contribute to its market leadership in molecular diagnostics, and we expect it to strengthen our position in this high-growth segment.”

The Fenwick transaction team was led by Doug Cogen and included corporate lawyers Michael Brown, Stephen Fisher, Morgan Sawchuk, Maureen Montgomery, Taylor Cashwell, Jeremy Kazzaz and Travis Robertson; intellectual property lawyers Ralph Pais, Joseph Schenck, Amy Hayden and Jung Yoo; antitrust lawyer Mark Ostrau; executive compensation and employee benefits lawyers Scott Spector and Patrick Grilli; and tax lawyers Will Skinner and Michael Knobler.

​​